Deck 2: Tumor-Immunity

Question 1

Which of the following is not a feature of chimeric antigen receptors (CARs)used in CAR-T cell therapy for cancers

A)MHC restricted antigen recognition
B)Costimulatory receptor signaling domains
C)ITAM motifs
D)Ig variable domains for antigen binding
E)Expressed by viral vectors

Answer 1

Expressed by viral vectors

Question 2

Which of the following is a correct description of checkpoint blocker drugs used in tumor immunotherapy?

A)Soluble Ig-fusion proteins that contain the extracellular domains of T cell inhibitory molecules
B)Blocking monoclonal antibodies specific for T cell growth factor IL-2
C)Small molecule inhibitors of JAK kinases involved in cytokine activation of T cells
D)Blocking monoclonal antibodies specific for T cell molecules that normally inhibit T cell activation
E)Blocking monoclonal antibodies specific for T cell molecules that normally enhance T cell activation

Answer 2

Blocking monoclonal antibodies specific for T cell molecules that normally inhibit T cell activation

Question 3

Which of the following description of T cell responses to tumor antigens is correct?

A)Most anti-tumor T cell responses are specific for mutant peptides bound to class II MHC molecules.
B)Cancer patients whose tumors have relatively high mutation burdens are less likely to mount effective -anti-tumor T cell responses.
C)The majority of anti-tumor T cell responses in cancer patients are specific for mutations,which contribute to the malignant phenotype of the cancer,inlcuding mutated cellular oncogenes or tumor suppressor genes.
D)The majority of anti-tumor T cell responses in cancer patents are specific for randomly mutated cellular proteins,which do not contribute to the malignant phenotype of the cancer.

E)Most T cell responses to tumors are specific for unmutated but over expressed tumor cell surface proteins.

Answer 3

The majority of anti-tumor T cell responses in cancer patents are specific for randomly mutated cellular proteins,which do not contribute to the malignant phenotype of the cancer.

Question 4

Which of the following statements about adaptive immune responses to cancers is true?

A)T cell responses only occur when the cancers harbor oncogenic viruses.
B)Antibody responses only occur when the cancer is harboring an oncogenic virus.
C)Both T cell and B cell responses often occur in patents with common forms of cancer,but those immune responses are usually ineffective in stopping progression of the cancer.
D)T cell responses often occur in patents with common forms of cancer,which are usually effective in stopping progression of the cancer
E)There is no evidence of T cell or antibody responses occurring to human tumors,without immunotherapy.

Question 5

A pathologist analyzes a resected colon with carcinoma,and she determines the tumor has penetrated deep into the colonic wall.Furthermore,there are a higher number of CD8+ T cells in and around the cancer,compared to most colon cancers analyzed in this way.What is the significance of the T cell finding?

A)Worse prognosis.
B)Better prognosis
C)No correlation with prognosis
D)More likely respond to anti-PD-1 therapy.
E)Patient likely to develop autoimmunity

Question 6

The most common averse effects of anti-PD-1 and anti-CTLA-4 therapy for tumors is which of the following?

A)Infections
B)Autoimmune organ dysfunction
C)Hypoglycemia
D)Stroke
E)Asthma